Tonix Pharmaceuticals is enrolling participants in a Phase 3 trial for fibromyalgia, the RALLY study.
For more information, please visit www.RALLYStudy.com or www.clinicaltrials.gov (NCT04508621).
- Home
- Investors
- News / Press Releases
- Press Releases
Press Releases
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA on TNX-601 CR for the Treatment of Major Depressive Disorder
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Compositions and Uses of Tianeptine Oxalate Salt, the Active Ingredient of TNX-601 CR
Tonix Pharmaceuticals Reports Positive COVID-19 Vaccine Efficacy Results in Non-Human Primates Vaccinated with TNX-1800 and Challenged with Live SARS-CoV-2
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in RALLY, the Second Phase 3 Study of TNX-102 SL for Management of Fibromyalgia
Tonix Pharmaceuticals to Participate in Upcoming March Investor Conferences
Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm)
Tonix Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference
Tonix Pharmaceuticals Holdings Corp. Closes $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules
Tonix Pharmaceuticals Holdings Corp. Prices $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules
Tonix Pharmaceuticals to Develop COVID-19 Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell Immunity
Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions
Tonix Pharmaceuticals Holdings Corp. Closes $40M Common Stock Offering Priced At-the-Market Under Nasdaq Rules
Tonix Pharmaceuticals Holdings Corp. Prices $40M Common Stock Offering Priced at-the-Market Under Nasdaq Rules
Tonix Pharmaceuticals to Participate in Upcoming January Conferences
Tonix Pharmaceuticals and Massachusetts General Hospital (MGH) Enter into Research Collaboration on Tonix’s Third Generation anti-CD40-Ligand Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Kidney Transplant Rejection
Tonix Pharmaceuticals Plans Commercial Scale Vaccine Manufacturing Facility
Tonix Pharmaceuticals Acquires Exclusive License to University of Geneva Technology for Oxytocin-Based Treatments for Treating Insulin Resistance, Diabetes and Obesity, Expanding Proprietary Uses for TNX-1900 (Intranasal Potentiated Oxytocin)
Tonix Pharmaceuticals Reports Topline Results from Phase 3 RECOVERY Study of TNX-102 SL in PTSD and Outlines Future Development Plans
Tonix Pharmaceuticals Announces Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia
Vaccine Genome Researchers Report 99.7% Colinear Identity Between a U.S. Civil War Era Smallpox Vaccine and Horsepox Virus
Tonix Pharmaceuticals Reports Positive Immune Response Results from COVID-19 Vaccine Candidate TNX-1800, Following Vaccination of Non-Human Primates
Tonix Pharmaceuticals Outlines New Statistical Method to Analyze Future PTSD Studies at the 3rd Annual Neuropsychiatric Drug Development Summit
Tonix Pharmaceuticals to Participate in Upcoming November Conferences
Tonix Pharmaceuticals to Present at 3rd Annual Neuropsychiatric Drug Development Summit
Tonix Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights
Tonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Facilitate Development of Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics
Tonix Pharmaceuticals to Participate in BIO Investor Forum Digital
Tonix Pharmaceuticals Announces Plan to Complete the Phase 3 RELIEF Study of TNX-102 SL for Management of Fibromyalgia with Currently Enrolled Participants Based on Results of Interim Analysis
Tonix Pharmaceuticals Completes Purchase of Facility to House Advanced Development Center (ADC) for Vaccine Programs
Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?
Tonix Pharmaceuticals Enrolls First Patient in COV-LOGIC, an Observational Study to Assess Antibody and T Cell Responses to SARS-CoV-2, the Virus that Causes COVID-19
Tonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study, the RALLY Study, of TNX-102 SL for the Management of Fibromyalgia
Tonix Pharmaceuticals to Participate in Upcoming September Virtual Investor Conferences
Tonix Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights
Tonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use Disorder
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 are Posted at the AAN Sports Concussion Virtual Conference
Tonix Pharmaceuticals to Participate in SNN Network Virtual Investor Conference
Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 Will be Presented in a Poster at the AAN Sports Concussion Virtual Conference
Tonix Pharmaceuticals Holding Corp. Announces Rescheduling of Special Meeting of Stockholders
Tonix Pharmaceuticals Announces Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics
Tonix Pharmaceuticals Holding Corp. Closes $10.5 Million Common Stock Registered Direct Offering
Tonix Pharmaceuticals Holding Corp. Prices $10,500,000 Common Stock Offering
Tonix Pharmaceuticals Enters into Research and Exclusive License Option Agreement with Kansas State University to Develop Vaccine Against COVID-19
Tonix Pharmaceuticals Completes Enrollment in Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia
Tonix Pharmaceuticals Plans Massachusetts R&D Facility to Accelerate Clinical Development of Vaccines and Protein-Based Therapeutics
Tonix Pharmaceuticals Announces Enrollment of Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia is Ahead of Schedule
Tonix Pharmaceuticals Announces Results from Preclinical Study of TNX-1700 Presented in a Poster at AACR Virtual Annual Meeting 2020
Tonix Pharmaceuticals and Southern Research Announce Expansion of COVID-19 Vaccine Collaboration
Tonix Pharmaceuticals Announces that Results from Preclinical Studies of TNX-1700 Will be Presented in a Poster at the AACR Virtual Annual Meeting 2020
Tonix Pharmaceuticals Announces Acquisition of Non-Addictive Migraine and Pain Treatment Programs from Trigemina and Assumption of License
Tonix Pharmaceuticals Announces Appointment of Richard H. Bagger to Board of Directors
Tonix Pharmaceuticals to Participate in Two June Virtual Investor Conferences
Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800
Tonix Pharmaceuticals Posted Results from Pharmacokinetic Analyses of TNX-102 SL and TNX-601 CR in Advance of Virtual Poster Presentations at the American Society of Clinical Psychopharmacology
Tonix Pharmaceuticals Announces Appointment of Herbert Harris, M.D., Ph.D., as Executive Vice President, Translational Medicine
Tonix Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights
Tonix Pharmaceuticals Enters into Research Collaboration and Exclusive License Agreement with University of Alberta to Develop Novel Horsepox-Based Vaccines, TNX-1810, TNX-1820 and TNX-1830, for the Prevention of COVID-19
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia
Tonix Pharmaceuticals to Deliver Virtual Presentation and Participate in Panel Discussion for Planet MicroCap Showcase Virtual Investor Conference 2020
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
Tonix Pharmaceuticals to Deliver Virtual Presentation for Spring Investor Summit
Tonix Pharmaceuticals Holding Corp. Closes $16,005,000 Common Stock Registered Direct Offering
Tonix Pharmaceuticals, Inc. Prices $16,005,000 Common Stock Offering Priced At-The-Market
Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800)
Tonix Pharmaceuticals Announces Closing of $7.5 million Public Offering
Tonix Pharmaceuticals Prices $7.5 million Public Offering
Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSD
Tonix Pharmaceuticals to Participate in Upcoming February Investor Conferences
Tonix Pharmaceuticals Presented Results from a Preclinical Study of TNX-801, a Potential Vaccine to Prevent Smallpox and Monkeypox, in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference
Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL
Tonix Pharmaceuticals to Present Results from Preclinical Study of TNX-801 in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference
Tonix Pharmaceuticals to Present at Biotech Showcase 2020
Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study
Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL
Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia
Tonix Pharmaceuticals to Present at 12th Annual LD Micro Main Event
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD
Tonix Pharmaceuticals to Participate in Benchmark’s Annual Discovery 1x1 Conference
Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia
Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder
Tonix Pharmaceuticals Announces Closing of $9.0 Million Public Offering
Tonix Pharmaceuticals Prices $9.0 Million Public Offering
Tonix Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights
Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya® for PTSD, Following FDA Meeting
Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX-601
Tonix Pharmaceuticals Joins the Alliance for Biosecurity
Tonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSD
Tonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mg
Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic Cancers
Tonix Pharmaceuticals Announces Publication of Paper on Triple Reuptake Inhibitor TNX-1600 (formerly D-578) in the European Journal of Pharmacology
Tonix Pharmaceuticals to Speak at the 2019 Annual National Association of Veterans’ Research and Education Foundations (NAVREF) Conference
Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences
Tonix Pharmaceuticals Doses Participants in Phase 1 Study Evaluating TNX-601 for the Daytime Treatment of Posttraumatic Stress Disorder
Tonix Pharmaceuticals and Massachusetts General Hospital Enter into Research Collaboration to Develop Tonix’s Third Generation Anti-CD154 Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Organ Transplant Rejection
Tonix Pharmaceuticals Expands Preclinical Pipeline with Triple Reuptake Inhibitor, TNX-1600, for the Treatment of PTSD
Tonix Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights
Tonix Pharmaceuticals Announces Director Stepping Down
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for the Composition and Formulation of TNX-102 SL
Tonix Pharmaceuticals Announces Closing of Public Offering of Common Stock
Tonix Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Tonix Pharmaceuticals Announces Issuance of Patent in China for the Composition and Formulation of TNX-102 SL
Tonix Pharmaceuticals Presented Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
Tonix Pharmaceuticals to Present at BIO 2019 International Convention
Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication
Tonix Pharmaceuticals to Speak at the Second Chance Digital Impact Recipient Gala
Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
Tonix Pharmaceuticals Announces Director Stepping Down
Tonix Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights
Tonix Pharmaceuticals Announces New Board Member, Daniel Goodman, M.D., MBA
Tonix Pharmaceuticals Announces Update on the Collaborative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA)
Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya® for the Treatment of Posttraumatic Stress Disorder
Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia
Tonix Pharmaceuticals to Present at Upcoming Investor Conferences
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights
Tonix Pharmaceuticals to Participate at Upcoming Investor Conferences
Tonix Pharmaceuticals Enrolls First Participant in the “RECOVERY” Study -- a New Phase 3 Trial of Tonmya® for the Treatment of Posttraumatic Stress Disorder
Tonix Pharmaceuticals Announces New European Use Patent for TNX-601
Tonix Pharmaceuticals Provides Update on Tonmya® for the Treatment of Posttraumatic Stress Disorder
Tonix Pharmaceuticals Announces Share Repurchase Program
Tonix Pharmaceuticals Announces New Board Member, James Treco
Tonix Pharmaceuticals to Present at BIO CEO & Investor Conference
Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
Tonix Pharmaceuticals Announces Closing of $15,000,000 Public Offering
Tonix Pharmaceuticals Prices $15,000,000 Public Offering
Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes
Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split
Tonix Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights
Tonix Pharmaceuticals Announces New Patent Coverage Protecting Tonmya®
Tonix Pharmaceuticals Presented Results and Retrospective Analyses of Phase 3 P301 “HONOR” Study in Poster Presentation at CNS Summit 2018
Tonix Pharmaceuticals to Present at BIO-Europe International Partnering Conference
Tonix Pharmaceuticals Announces Innovative Design in Next Phase 3 Study of Tonmya® for PTSD, Following FDA Meeting
Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in Poster Presentations at CNS Summit 2018
Tonix Pharmaceuticals to Present at the Dawson James Securities Small Cap Growth Conference
Tonix Pharmaceuticals to Present at the MicroCap Conference
Tonix Pharmaceuticals to Present at Sidoti & Company Fall 2018 Investor Conference
Tonix Pharmaceuticals Announces New Board Member, Oye Olukotun, M.D.
Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences
Tonix Pharmaceuticals Announces Director Stepping Down
Tonix Pharmaceuticals Presents Results and Retrospective Analyses of Two Double-Blind, Randomized Placebo-Controlled 12-Week Studies of Tonmya® in Military-Related PTSD at the 2018 Military Health System Research Symposium
Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in a Poster Presentation at the 2018 Military Health System Research Symposium
Tonix Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights
Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 HONOR Study of Tonmya® in Military-Related PTSD
Tonix Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for TNX-102 SL for Treatment of Agitation in Alzheimer’s Disease
Tonix Pharmaceuticals Presented New Data Related to Suicidal Ideation and Behaviors in Military-Related PTSD from the Phase 2 AtEase Study at the American Society of Clinical Psychopharmacology
Tonix Pharmaceuticals to Present at the 2018 BIO International Convention
Tonix Pharmaceuticals Reports Preliminary Results from a Phase 1 Pivotal Multiple-Dose Bridging Pharmacokinetic (PK) Study of Tonmya® or TNX-102 SL
Tonix Pharmaceuticals to Present at the 2018 American Society of Clinical Psychopharmacology
Tonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update
Tonix Pharmaceuticals to Present at the BIO KOREA 2018 International Convention
Tonix Pharmaceuticals Receives IND Clearance by U.S. FDA for TNX-102 SL in Agitation in Alzheimer’s Disease
Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD
Tonix Pharmaceuticals Expands Intellectual Property Portfolio for TNX-102 SL
Tonix Pharmaceuticals to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Programs Update
Tonix Pharmaceuticals to Present at the 30th Annual ROTH Conference
Tonix Pharmaceuticals Appoints David L. Grange to the Board of Directors
Tonix Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York City
Tonix Pharmaceuticals to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference in Fort Lauderdale
Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)
Tonix Pharmaceuticals Announces Publication Reporting Synthesis, Construction and Characterization of a Potential Smallpox-Preventing Vaccine Candidate TNX-801 (Live Horsepox Virus from Cell Culture)
Tonix Pharmaceuticals Appoints Jessica Morris as Chief Operating Officer
Tonix Pharmaceuticals to Present at Sachs Associates Neuroscience Innovation Forum and Biotech Showcase 2018 in San Francisco
Tonix Pharmaceuticals Completes Positive Pre-IND Meeting with FDA for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) as a Clinical Candidate for Agitation in Alzheimer’s Disease
Tonix Pharmaceuticals to Present at 10th Annual LD Micro Investor Conference
Tonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs Update
Tonix Pharmaceuticals to Present at 23rd Annual BIO-Europe International Partnering Conference
Tonix Pharmaceuticals Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) for PTSD
Tonix Pharmaceuticals to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference
Tonix Pharmaceuticals Presented at the 2nd Annual Cohen Veterans Care Summit in Washington, D.C.
Tonix Pharmaceuticals Receives European Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)
Tonix Pharmaceuticals Elects Margaret Smith Bell to the Board of Directors
Tonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
Tonix Pharmaceuticals Presented Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing Phase 3 Trial at the 2017 Military Health System Research Symposium
Tonix Pharmaceuticals to Present Additional Phase 2 Clinical Results and Design of Ongoing Phase 3 Trial in Military-Related PTSD at the 2017 Military Health System Research Symposium
Tonix Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Programs Update
Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya® as Proposed Brand Name for TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD
Tonix Pharmaceuticals to Present at the 2017 BIO International Convention
Tonix Pharmaceuticals Participated in the "Pathophysiology of Posttraumatic Stress Disorder: Rethinking Drug Targets” Summit Sponsored by U.S. Department of Defense
Tonix Pharmaceuticals to Present an Update of FDA Designated Breakthrough Therapy-TNX-102 SL for PTSD at the 2017 Marcum MicroCap Conference
Tonix Pharmaceuticals Presented Retrospective Analyses of Treatment Response and Remission to TNX-102 SL in a Phase 2 Military-Related PTSD Study
Tonix Pharmaceuticals to Present Additional Clinical Results of Military-Related PTSD Study at the 2017 American Society of Clinical Psychopharmacology Annual Meeting
Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD
Tonix Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Programs Update
Tonix Pharmaceuticals to Present PTSD Clinical Data at the Society of Biological Psychiatry 72nd Annual Scientific Convention
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-102 SL Composition and Formulation: Designed for Transmucosal Absorption and Bedtime Daily Use
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Programs Update
Tonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
Tonix Pharmaceuticals Reports Results from U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting on TNX-102 SL for Posttraumatic Stress Disorder
Tonix Pharmaceuticals Completes $8 Million Public Offering of Common Stock
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
Tonix Pharmaceuticals Prices Public Offering of 1,800,000 Shares of Common Stock
Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at The MicroCap Conference
Tonix Pharmaceuticals Enrolls First Participant in Military-Related PTSD Phase 3 Trial of FDA Breakthrough Therapy-Designated TNX-102 SL
Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program at Oppenheimer’s 27th Annual Healthcare Conference
Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent Covering Composition and Manufacture of TNX-102 SL
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the 29th Annual ROTH Conference
Tonix Pharmaceuticals Announces Demonstrated Vaccine Activity in First-Ever Synthesized Chimeric Horsepox Virus
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the Cowen and Company 37th Annual Health Care Conference
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the 2017 BIO CEO & Investor Conference
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at NobleCon13
Tonix Pharmaceuticals Presented Details of Newly Expanded Product Development Pipeline at 9th Annual Biotech Showcase Conference
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at 9th Annual Biotech Showcase Conference
Tonix Pharmaceuticals’ PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDA
Tonix Pharmaceuticals Presented New Clinical Results from Sub-Group Analysis of Phase 2 AtEase Study in Military-Related Posttraumatic Stress Disorder (PTSD)
Tonix Pharmaceuticals to Present Clinical Data at the 55th Annual Meeting of the American College of Neuropsychopharmacology (ACNP)
Tonix Pharmaceuticals to Present at 9th Annual LD Micro Main Event Investor Conference
Tonix Pharmaceuticals Reports Third Quarter 2016 Financial Results
Tonix Pharmaceuticals to Present New Clinical Results from Retrospective Analysis of Phase 2 AtEase Study in Military-Related PTSD
Tonix Pharmaceuticals to Present Clinical Data at the International Society for Traumatic Stress Studies (ISTSS) 32nd Annual Meeting
Tonix Pharmaceuticals to Present at 22nd Annual BIO-Europe® International Partnering Conference
Tonix Pharmaceuticals to Present Clinical Data at the 2016 Neuroscience Education Institute (NEI) Psychopharmacology Congress
Tonix Pharmaceuticals Completes $5.2 Million Underwritten Public Offering
Tonix Pharmaceuticals to Present Clinical Data at CNS Summit 2016
Tonix Pharmaceuticals Prices $5.2 Million Underwritten Public Offering
Tonix Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Warrants
Tonix Pharmaceuticals to Host Posttraumatic Stress Disorder (PTSD) Awareness Day
UPDATE -- Tonix Pharmaceuticals to Present at Dawson James Securities 2016 Small Cap Growth Stock Conference
Tonix Pharmaceuticals to Present at Dawson James Securities 2016 Small Cap Growth Stock Conference
Tonix Pharmaceuticals to Present at 16th Annual Sachs Biotech in Europe Forum
Tonix Pharmaceuticals to Present at Rodman & Renshaw 18th Annual Global Investment Conference
Tonix Pharmaceuticals Reports Topline Results from Phase 3 AFFIRM Study of TNX-102 SL in Fibromyalgia and Provides Corporate Update
Tonix Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for TNX-102 SL in Post-Traumatic Stress Disorder
Tonix Pharmaceuticals Presents Poster on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2016 Military Health System Research Symposium
Tonix Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Programs Update
Tonix Pharmaceuticals Initiates Second Pivotal Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia
Tonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
Tonix Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
Tonix Pharmaceuticals Completes $10 Million Public Offering of Common Stock
Tonix Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
Tonix Pharmaceuticals Prices Underwritten Public Offering of Common Stock
Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
Tonix Pharmaceuticals Presents at EULAR Results of a Retrospective Analysis from the Phase 2b BESTFIT Clinical Study of TNX-102 SL in Fibromyalgia
Tonix Pharmaceuticals to Present at the 2016 BIO International Convention
Tonix Pharmaceuticals Presents Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) at the American Society of Clinical Psychopharmacology (ASCP) 2016 Annual Meeting
Tonix Pharmaceuticals to Present Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the ASCP 2016 Annual Meeting
Tonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD)
Tonix Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Programs Update
Tonix Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of TNX-102 SL in Fibromyalgia
Tonix Pharmaceuticals to Present at the 10th Annual BIO Europe Spring Conference
Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting
Tonix Pharmaceuticals to Present at the 28th Annual ROTH Conference
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Programs Update
Tonix Pharmaceuticals to Present at Two Investor Conferences in March 2016
Tonix Pharmaceuticals Appoints Chief Financial Officer
Tonix Pharmaceuticals Reports Top Line Results From Phase 2 Proof-of-Concept Clinical Study of TNX-201 in Episodic Tension-Type Headache
Tonix Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference
Tonix Pharmaceuticals Announces Management Change
Tonix Pharmaceuticals to Present at Biotech Showcase 2016
Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD)
Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Study of TNX-201 in Episodic Tension-Type Headache
Tonix Pharmaceuticals and U.S. Department of Defense Military Developer in Partnership to Expand Efforts to Examine TNX-102 SL for Post-Traumatic Stress Disorder
Tonix Pharmaceuticals to Participate in Fireside Chat at the Oppenheimer 26th Annual Healthcare Conference
Tonix Pharmaceuticals Presents Additional Data on Tonmya(TM) Demonstrating Improvements in Sleep, Pain, and Other Outcomes in Fibromyalgia at 2015 ACR/ARHP Annual Meeting
Tonix Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Programs Update
Tonix Pharmaceuticals Announces Acceptance of Three Abstracts to be Presented at the 2015 ACR/ARHP Annual Meeting
Tonix Pharmaceuticals to Present at the 15th Annual Biotech in Europe Forum for Global Partnering and Investment
Tonix Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference
Tonix Pharmaceuticals Presents on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2015 Military Health System Research Symposium
Tonix Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Program Update
Tonix Pharmaceuticals Appoints Mark T. Edgar, PhD as Senior Vice President of Product Development
Tonix Pharmaceuticals Closes $20.1 Million Public Offering of Common Stock
Tonix Pharmaceuticals Prices Underwritten Public Offering of Common Stock
Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
Tonix Pharmaceuticals Presents Non-clinical Data on TNX-201 at the 57th Annual Scientific Meeting of the American Headache Society
Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya as Proposed Brand Name for Cyclobenzaprine HCl Sublingual Tablets, 2.8 mg
Tonix Pharmaceuticals Initiates Phase 2 Clinical Study of TNX-201 in Episodic Tension-Type Headache
Tonix Pharmaceuticals Presents Additional Data From Phase 2b BESTFIT Clinical Study at EULAR
Tonix Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference
Tonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR
Tonix Pharmaceuticals Presents Data at the Annual Meeting of the Society for Biological Psychiatry
Tonix Pharmaceuticals Launches Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia
Tonix Pharmaceuticals Reports First Quarter 2015 Financial Results and Clinical Update
Tonix Pharmaceuticals to Present at the 12th Annual BIO Asia International Conference
Tonix Pharmaceuticals to Present at the 27th Annual ROTH Conference
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
Tonix Pharmaceuticals to Present at the 8th Annual European Life Sciences CEO Forum
Tonix Pharmaceuticals Announces Closing of $28.7 Million Public Offering of Common Stock
Tonix Pharmaceuticals to Present at the BIO CEO & Investor Conference
Tonix Pharmaceuticals Prices Underwritten Public Offering of Common Stock
Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
Tonix Pharmaceuticals Commences Phase 2 Trial of TNX-102 SL in Post-Traumatic Stress Disorder
Tonix Pharmaceuticals to Present at the Noble Financial Annual Investor Conference
Tonix Pharmaceuticals Announces Clinical Progress on Potential Treatment for Headache
Tonix Pharmaceuticals Provides Clinical and Regulatory Update on its Continued Development of TNX-102 SL in Fibromyalgia
Tonix Pharmaceuticals to Present at the LD Micro Investor Conference
Tonix Pharmaceuticals Reports Third Quarter 2014 Financial Results
Tonix Pharmaceuticals Receives IND Clearance for TNX-201 in Episodic Tension-Type Headache
Tonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial of TNX-102 SL in Patients With Fibromyalgia
Tonix Pharmaceuticals to Present at the BioCentury NewsMakers Conference
Tonix Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference
Tonix Pharmaceuticals Announces Transfer to the NASDAQ Global Market
Tonix Pharmaceuticals Reports Second Quarter 2014 Financial Results
Tonix Pharmaceuticals to Present at Two Investor Conferences in August
Tonix Pharmaceuticals Announces Registered Direct Offering of $7.8 Million
Tonix Pharmaceuticals Joins Russell Microcap Index
Tonix Pharmaceuticals Appoints Ronald R. Notvest, Ph.D. as Senior Vice President of Commercial Planning and Development
Tonix Pharmaceuticals Receives IND Clearance From U.S. Food and Drug Administration for TNX-102 SL in Post-Traumatic Stress Disorder
Tonix Appoints Gregory M. Sullivan, M.D. as Chief Medical Officer
Tonix Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference
Tonix Pharmaceuticals to Present at the LD Micro Invitational Conference
Tonix Pharmaceuticals to be Added to the MSCI Global Micro Cap Index
Tonix Pharmaceuticals to Present at the MIXiii Biomed Conference in Israel
Tonix Pharmaceuticals Reports First Quarter 2014 Financial Results
Tonix Pharmaceuticals Completes Enrollment in BESTFIT Trial of TNX-102 SL for Fibromyalgia
Tonix Pharmaceuticals Spotlighted in April 7 Issue of BioCentury
Tonix Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, Clinical Development and Regulatory Affairs
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
Tonix Pharmaceuticals to Present at the ROTH Conference
Tonix Pharmaceuticals Completes Pre-IND Meeting With FDA on TNX-201 for Episodic Tension-Type Headache: Clinical Development to Begin in 4Q 2014
Tonix Pharmaceuticals Spotlighted in Three Media Outlets in February
Tonix Pharmaceuticals to Present at the BIO CEO Conference
Tonix Pharmaceuticals Announces Closing of $43.5 Million Public Offering of Common Stock
Tonix Pharmaceuticals Prices Underwritten Public Offering Raising $43.5 Million
Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
Tonix Pharmaceuticals Announces the Enrollment of Completers From the BESTFIT Trial Into a 12-Month Open-Label Extension Study
Tonix Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Tonix Pharmaceuticals to Present at the LD Micro Conference
Tonix Pharmaceuticals Reports Third Quarter 2013 Financial Results
Tonix Pharmaceuticals Partners With the American Chronic Pain Association to Help Raise Awareness About Fibromyalgia
Tonix Pharmaceuticals to Participate in the Women's Healthcare Innovation and Leadership Showcase on October 15, 2013
Tonix Pharmaceuticals Initiates Enrollment in Phase 2b BESTFIT Trial of TNX-102 SL in Fibromyalgia Patients
Tonix Pharmaceuticals to Present at the First Global Life Sciences Conference in Warsaw, Poland on September 17, 2013
Tonix Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on September 9, 2013
Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome
Tonix Pharmaceuticals Announces Closing of Public Offering
Tonix Pharmaceuticals Announces Pricing of Public Offering of Units and NASDAQ Listing
Tonix Pharmaceuticals Announces Reverse Split of Common Stock
Tonix Pharmaceuticals to Hold Annual Shareholders' Meeting on April 19, 2013
TONIX Completes Pre-Phase 3 Meeting With U.S. Food and Drug Administration for TNX-102 SL in Fibromyalgia
Tonix Pharmaceuticals to Present at the SeeThruEquity MicroCap Investor Forum on March 12
Tonix Pharmaceuticals to Present at Upcoming Conferences
Tonix Pharmaceuticals Completes $1 Million Financing With Technology Partners
Tonix Pharmaceuticals Completes Private Placement
Tonix Pharmaceuticals to Present at Fifth Annual LD Micro Conference
Tonix Pharmaceuticals Completes Convertible Note Offering
Tonix Pharmaceuticals Presents Research Findings at the 2012 American College of Rheumatology Annual Scientific Meeting
TONIX Pharmaceuticals Completes Pre-IND Meeting With FDA for Potential New Treatment for Post-Traumatic Stress Disorder
Tonix Pharmaceuticals Confirms Clinical Utility of TNX-102 Sublingual Tablet
Tonix Pharmaceuticals to Present at 2012 AEGIS Healthcare Conference
Tonix Pharmaceuticals Highlights Therapeutic Programs on CEONEWS.Tv
TONIX Pharmaceuticals Announces Poster Presentation at the 2012 American College of Rheumatology Annual Scientific Meeting
TONIX Pharmaceuticals' CEO Discusses the Company's New Treatment for Fibromyalgia on News-Medical.net
TONIX Pharmaceuticals to Present at Rodman & Renshaw 14th Annual Global Investment Conference on September 11
Tonix Pharmaceuticals' CEO Highlights Connection Between Disturbed Sleep and New Treatment for Fibromyalgia and Post-Traumatic Stress Disorder on KIDELA TV
Tonix Pharmaceuticals Issues Letter to Shareholders
Tonix Pharmaceuticals CEO Dr. Seth Lederman Describes Potential Treatment for Fibromyalgia, Post-Traumatic Stress Disorder and Traumatic Brain Injury
Tonix Pharmaceuticals Reports That Sublingual Formulation of Fibromyalgia Drug Reduces Production of a Psychoactive Metabolite, Improving Suitability for Long-Term, Chronic Treatment
Tonix Pharmaceuticals Announces Completion of Clinical Trial of Sublingual TNX-102
Tonix Pharmaceuticals Reports Positive Preclinical Data on Sublingual TNX-102
Tonix Pharmaceuticals to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
Tonix Pharmaceuticals Receives Health Canada Clearance to Study a Novel Treatment for Fibromyalgia
Tonix Pharmaceuticals to Present at Marcum MicroCap Conference
Tonix Pharmaceuticals Featured on GLX-TV OpenCEOLive Series
Tonix Pharmaceuticals CEO Interviewed on CEOLive.TV
CORRECTING and REPLACING Tonix Pharmaceuticals Appoints Dr. Samuel Saks to Its Board of Directors
TONIX Pharmaceuticals to Present at Three Investor Conferences in May
TONIX Pharmaceuticals Completes Pharmacokinetic Study on New Formulation of TNX-102 for Fibromyalgia
TONIX Pharmaceuticals Strengthens Management Team with the Appointments of Its New Chief Financial Officer and Senior Director of Drug Development
TONIX Pharmaceuticals Holding Corp. Closes on Net Proceeds of $2.0 Million in Second Tranche of a $6.6 Million Private Placement
TONIX Pharmaceuticals to Present at the 14th Annual Bio CEO & Investor Conference on February 14, 2012
TONIX Pharmaceuticals Closes $4.3 Million Private Placement
Tonix Pharmaceuticals to Present at Biotech Showcase and OneMedForum Conferences in San Francisco on January 9 and 10, 2012
TONIX Pharmaceuticals to Present at the New York Society of Security Analysts’ 15th Annual Biotech and Specialty Pharmaceuticals Conference on November 30, 2011
Tonix Pharmaceuticals Receives FDA Clearance to Initiate a Pharmacokinetic Study of TNX-102 For Fibromyalgia
Tamandare Explorations Inc. Announces Name Change to Tonix Pharmaceuticals Holding Corp.
TONIX Pharmaceuticals and Tamandare Explorations Announce Completion of Share Exchange Transaction and Private Placement
Tonix Pharmaceuticals' Bedtime Very Low Dose Cyclobenzaprine Study Featured in Journal of Rheumatology
Tonix Pharmaceuticals Elects Charles Mather to its Board of Directors
Tonix Pharmaceuticals Elects Harvey Moldofsky, M.D., to its Scientific Advisory Board
TONIX Pharmaceuticals Presents Findings on the Effects of Bedtime Very Low Dose (VLD) Cyclobenzaprine (CBP) on Symptoms and Sleep Physiology in Patients with Fibromyalgia Syndrome
TONIX Pharmaceuticals Reports Analysis of Phase 2a Study of Very Low Dosage Cyclobenzaprine in Fibromyalgia Syndrome (FMS)
TONIX Pharmaceuticals Elects Ernest Mario, PhD, to its Board of Directors
